What Does Wall Street See for Auxilium Pharmaceuticals' Q2?
Auxilium Pharmaceuticals (NAS: AUXL) is expected to report Q2 earnings on July 31. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Auxilium Pharmaceuticals' revenue will increase 12.4% and EPS will remain in the red.
The average estimate for revenue is $74.1 million. On the bottom line, the average EPS estimate is -$0.05.
Last quarter, Auxilium Pharmaceuticals logged revenue of $73.6 million. GAAP reported sales were 26% higher than the prior-year quarter's $58.4 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at -$0.04. GAAP EPS were -$0.04 for Q1 against -$0.25 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 77.4%, 340 basis points worse than the prior-year quarter. Operating margin was -2.6%, 1,750 basis points better than the prior-year quarter. Net margin was -2.4%, 1,790 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $305.0 million. The average EPS estimate is -$0.21.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 124 members out of 181 rating the stock outperform, and 57 members rating it underperform. Among 48 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 24 give Auxilium Pharmaceuticals a green thumbs-up, and 24 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Auxilium Pharmaceuticals is outperform, with an average price target of $21.92.
Over the decades, small-cap stocks like Auxilium Pharmaceuticals have provided market-beating returns, provided they're value-priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: Two Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.
Add Auxilium Pharmaceuticals to My Watchlist.
The article What Does Wall Street See for Auxilium Pharmaceuticals' Q2? originally appeared on Fool.com.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.